About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

ENGLEWOOD, Colo., Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of Californi ...

Core Insights - Zynex, Inc. has completed its clinical verification trial for the NiCO™ pulse oximeter, a significant step towards FDA submission for market clearance [1][2][5] - The NiCO pulse oximeter employs advanced laser technology for direct measurement of blood oxygenation, addressing inaccuracies found in traditional LED-based devices, particularly for individuals with darker skin [3][4] - The company aims to penetrate the multi-billion dollar pulse oximetry market with the NiCO product line, emphasizing its precision, accuracy, and safety as key competitive advantages [4][6] Company Developments - The completion of the verification study is described as a pivotal event for Zynex Monitoring Solutions, marking the transition to final testing before the FDA submission [2][5] - Zynex's President highlighted the collaborative effort behind the study's success and the company's readiness to submit for FDA clearance [5] - The CEO expressed excitement about entering a mature and growing market with the NiCO product, which is expected to leverage its innovative capabilities [6]

ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member.The Open Oximetry Project, an initiative led by the University of California, San Francisco' ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Company Performance - Zynex Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.10 per share a year ago, representing a 40% earnings surprise [1] - The company posted revenues of $49.97 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.86%, and showing a slight increase from $49.92 million year-over-year [1] - Over the last four quarters, Zynex has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [1] Stock Outlook - Zynex shares have declined approximately 23.2% since the beginning of the year, contrasting with the S&P 500's gain of 21.5% [2] - The company's earnings outlook is uncertain, with unfavorable estimate revisions leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] - Current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $53.85 million, and for the current fiscal year, it is $0.20 on revenues of $200.66 million [4] Industry Context - The Medical - Products industry, to which Zynex belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Another company in the same industry, Curaleaf Holdings, Inc., is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of +33.3%, with revenues projected at $348.52 million, up 4.6% from the previous year [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) Common Stock, par value $0.001 p ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Exhibit 99.1 Zynex Reports Third Quarter 2024 Financial Results ENGLEWOOD, Colo., October 24, 2024 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024. Key Third Quarter Highlights and Business Update ● Q3 2024 orders increased 13% year-over-year. ● Q3 2024 ...

ENGLEWOOD, Colo., Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024.Key Third Quarter Highlights and Business Update Q3 2024 orders increased 13% year-over-year. Q3 2024 net revenue of $50.0 million. Q3 2024 net income of $2.4 mi ...